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Summary  The  emergence  of  drug-resistant  tuberculosis  (TB)  is  an  increasing  prob-
lem  which  adversely  affects  patient  care  and  public  health.  This  study  aimed  to
determine  the  rates  and  patterns  of  primary  anti-TB  drugs  resistance  in  Najran,
Southwestern  Saudi  Arabia.  The  study  included  80  smear-positive  new  pulmonary  TB
patients.  Sputum  samples  were  cultured  on  Lowenstein—Jensen  and  Middle-Brook
7H10  media.  Mycobacterium  tuberculosis  susceptibility  testing  was  done  by  the  con-
ventional  agar  proportion  method  for  isoniazide  (INH),  rifampicin  (RIF),  streptomycin
(SPM)  and  ethambutol  (EMB).  Out  of  the  68  M.  tuberculosis  isolates,  42  (61.8%)  were
sensitive  to  all  4  drugs  and  26  (38.2%)  were  resistant  to  one  or  more  drugs.  The  most
common  resistance  was  found  to  INH  (33.8%),  followed  by  RIF  (23.5%),  SPM  (13.2%)
and  EMB  (2.9%).  Eight  (11.8%)  isolates  were  resistant  to  one  drug,  14  (20.6%)  were
resistant  to  2  drugs,  3  (4.4%)  were  resistant  to  3  drugs  and  one  (1.5%)  was  resistant
to  4  drugs.  Multi-drug  resistant  (MDR)  isolates  were  found  in  14  (20.6%)  cases.  In
conclusion,  the  primary  resistance  rate  to  four  ﬁrst-line  anti-tuberculous  drugs  and
MDR-TB  rate  are  worryingly  high,  representing  an  alarming  situation  in  Najran.  Fur-
ther  studies  are  necessary  for  continuous  surveillance  of  M.  tuberculosis  resistance
patterns.
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he  World  Health  Organization  (WHO)  estimated
he global  burden  of  tuberculosis  in  2009  to  be
.4 million  incident  patients,  14  million  preva-
ent cases  and  2.4  million  deaths  [1].  Saudi  Arabia
as a  moderate  TB  infection  rate  compared  with
ther developing  countries.  A  recent  Saudi  study
2] evaluating  changes  TB  incidence  rates  in  13
rovinces  found  that  the  TB  incidence  rates  were
1.8—12.1  per  100,000  individuals  between  2005
nd 2009.  The  investigators  reported  that  the
 Sciences. Published by Elsevier Ltd. All rights reserved.
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yearly  TB  incidence  rate  was  signiﬁcantly  increasing
among  Saudis  in  Najran  (21.3%)  and  Riyadh  (8.5%)
and signiﬁcantly  decreasing  in  non-Saudis  in  Baha
(23.1%), Hail  (17.4%)  and  the  eastern  region  of  Saudi
Arabia (22.6%).
The emergence  of  drug-resistant  Mycobacterium
tuberculosis  strains  has  proven  to  be  a  difﬁcult
problem and  is  one  of  the  greatest  public  health
threats  worldwide.  Multidrug-resistant  TB  (MDR-TB)
is deﬁned  as  having  resistance  to  at  least  isoni-
azid (INH)  and  rifampicin  (RIF),  the  2  principal
ﬁrst-line anti-TB  drugs.  MDR-TB  poses  an  impor-
tant threat  to  TB  control  because  it  reduces  the
response  to  standard  short-course  chemotherapy
with ﬁrst-line  anti-TB  drugs,  leads  to  higher  mor-
tality and  treatment  failure  rates,  and  increases
the period  of  disease  transmissibility  [3,4].  The
underlying  causes  of  MDR-TB  have  been  suggested
to be  incorrect  treatment,  poor  compliance  and
erratic drug  ingestion,  poor  drug  absorption  or  fre-
quent or  prolonged  shortages  of  anti-TB  drugs,
which result  from  ﬁnancial  constraints  in  a  num-
ber of  developing  countries  [5,6].  Approximately
250,000 TB  patients  identiﬁed  in  2009  had  multi-
drug resistant  TB  (MDR-TB),  and  440,000  MDR-TB
cases  were  identiﬁed  in  2008  [7].  The  prevalence
of single-drug-resistant  TB  or  MDR-TB  in  the  King-
dom of  Saudi  Arabia  is largely  unknown  because
only a  few  studies  conﬁned  to  large  centers  have
been completed  [8—13].  Unfortunately,  there  are
no previous  reports  on  M.  tuberculosis  susceptibil-
ity in  Najran,  which  is  located  in  southwestern  Saudi
Arabia. The  prompt  detection  of  anti-TB  drug  resis-
tance is  essential  for  controlling  the  development
and spread  of  MDR-TB  because  detection  facili-
tates the  appropriate  and  timely  delivery  of  anti-TB
therapy,  reduces  the  overall  cost  of  treatment,  min-
imizes the  risk  of  developing  further  resistance  and
limits the  spread  of  drug-resistant  M.  tuberculosis
[14].
This study  aimed  to  determine  the  rates  and  pat-
terns of  primary  anti-TB  drug  resistance  in  Najran,
southwestern  Saudi  Arabia.  It  is  our  intention  that
these data  can  not  only  be  used  locally  but  also  in
conjunction  with  related  studies  from  other  regions
of the  Kingdom  and  worldwide  to  highlight  the
extent  of  the  problem  in  the  community  and  to  help
in planning  and  implementing  successful  treatment
programs.Materials and methods
A  total  of  80  smear-positive,  newly  diagnosed  pul-
monary TB  patients  from  the  Chest  and  Fever
l
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ospital  and  King  Khalid  Hospital  in  Najran  were
ncluded  in  this  study.  The  patients  were  iden-
iﬁed between  March  2009  and  August  2011.
ew TB  cases  were  deﬁned  as  TB  patients  who
ad never  been  treated  with  anti-tuberculous
rugs or  had  received  the  drugs  for  less  than
 month  [1].
Three  consecutive  sputum  samples  were  col-
ected from  each  patient  and  were  sent  to
he microbiology  department  of  the  Najran
niversity College  of  Medicine  for  further  process-
ng.
Each  specimen  was  processed  with  the  N-
cetyl-L-Cysteine  sodium  hydroxide  (NALC-NaOH)
ethod and  cultivated  on  Lowenstein—Jensen
L—J) (BioMerieux,  Marcy  l’Etoile,  France)  and
iddle-Brook  7H10  (Difco  Laboratories,  Detroit,
SA) media  as  described  by  Kent  and  Kubica  [15].
he cultures  were  incubated  at  37 ◦C  for  up  to
 months.  The  suspected  colonies  were  identiﬁed
y Kinyoun-stained  smears,  niacin  accumulation
sing niacin  TB  test  strips  (Difco  Laborato-
ies), nitrate  reduction  using  nitrate  test  strips
Difco Laboratories)  and  heat-stable  catalase  tests
15].
All of  the  M.  tuberculosis  isolates  were
ested for  susceptibility  to  INH,  RIF,  strepto-
ycin (SPM)  and  ethambutol  (EMB)  with  the
onventional proportion  method  on  antibiotic-
ree and  antibiotic-incorporated  Middle-Brook
H10 agar  plates  containing  OADC  (oleic
cid—albumin—dextrose—catalase)  enrichment.
he critical  drug  concentrations  were  0.2,  1.0,
.0 and  5.0  g/ml  for  INH,  RIF,  SPM  and  EMB,
espectively. An  M.  tuberculosis  isolate  was  con-
idered drug-resistant  if  the  number  of  colonies  on
he drug-containing  media  was  1%  or  more  of  the
olonies  on  the  drug-free  media  [15].
esults
ixty-eight  of  the  80  cases  in  this  study  exhib-
ted sputum  cultures  that  were  positive  for  M.
uberculosis. Contamination  occurred  in  4  cases,
on-tuberculous  mycobacteria  were  present  in  3
ases, and  5  cases  did  not  exhibit  mycobacterial
rowth. Forty-two  (61.8%)  of  the  68  M.  tuberculosis
solates were  sensitive  to  all  4  drugs,  and  26  (38.2%)
solates  were  resistant  to  one  or  more  drugs.  The
olonies  were  primarily  resistant  to  INH  (33.8%)  fol-
owed by  RIF  (23.5%),  SPM  (13.2%)  and  EMB  (2.9%)
Table 1).
The resistance  patterns  of  the  M.  tuberculosis
solates are  presented  in  Table  2.  Eight  (11.8%)  of
Primary  anti-tuberculous  drugs  resistance  of  pulmonary
Table  1  Susceptibility  patterns  of  the  68  M.  tuber-
culosis  isolates  to  4  anti-tuberculosis  drugs.
Name  of  drugs  Sensitive
isolates
No.  (%)
Resistant
isolates
No. (%)
Isoniazide 45 (66.2)  23  (33.8)
Rifampicin 52 (76.5)  16 (23.5)
Streptomycin 59 (86.8)  9 (13.2)
Ethambutol 66 (97.1)  2 (2.9)
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sSensitive  to  all  drugs  42  (61.8)  —
Resistant  to  all  drugs  —  26  (38.2)
he  isolates  were  resistant  to  one  drug,  14  (20.6%)
ere  resistant  to  2  drugs,  3  (4.4%)  were  resis-
ant to  3  drugs,  and  one  (1.5%)  was  resistant  to
 drugs.  MDR  isolates  were  found  in  14  (20.6%)
ases.
iscussion
he  observed  overall  drug  resistance  rate  of  38.2%
s higher  than  that  reported  in  previous  Saudi  stud-
es, which  found  values  ranging  from  8.7%  to  30%
8—13]. Schiott  et  al.  [16]  reported  a 43.7%  resis-
ance  rate  after  investigating  patients  in  Jazan.
he investigators  attributed  this  ﬁnding  to  Jazan’s
roximity  to  Yemen,  which  reportedly  has  one  of
he highest  rates  of  active  TB  among  Arab  coun-
ries. Workers  moving  across  the  border  might  be
he cause  for  the  high  resistance  rate.  Najran  is
lso very  close  to  Yemen  geographically,  and  this
esistance  rate  represents  a  highly  alarming  situa-
ion. The  Global  Project  on  Anti-tuberculous  Drug
esistance  Surveillance  (GPADRS)  investigated  the
revalence of  TB  in  83  countries  from  2002  to  2007
17] and  found  that  the  median  prevalence  of  pri-
ary resistance  to  any  drug  was  11.1%  and  that
esistance values  ranged  from  0%  in  Iceland  to  56.3%
n Azerbaijan.  The  data  from  Arab  countries  showed
3
r
D
2
Table  2  Resistance  patterns  of  drug-resistant  M.  tuberculo
Number  of
drugs
Name  of
drugsa
One  drug
INH  
RIF  
SPM  
EMB  
Two  drugs
INH  +  RIF  
INH  +  SPM  
Three  drugs  INH  +  RIF  +  SPM  
Four  drugs INH  +  RIF  +  SPM  +  EMB  
MDR
a INH, isoniazide; RIF, rifampicin; SPM, streptomycin; EMB, etham tuberculosis  in  Southwestern  Saudi  Arabia  283
rimary  resistance  rates  of  10%  in  Oman,  35%  in
ordan and  49%  in  Yemen.
The rate  of  resistance  to  anti-tuberculous  agents
s an  important  parameter  for  implementing  control
easures  and  planning  successful  treatment  pro-
rams. Resistance  to  INH  as  a  single  drug  occurred
ost frequently  (5.9%)  in  our  study.  Reports  from
ifferent  regions  in  Saudi  Arabia  have  shown  INH
esistance  rates  of  4.4—19.4%  in  Riyadh  [8,9],
0.3—28.7%  in  Jeddah  [10,11],  9.5—17%  in  Dammam
12,13],  6.5%  in  Taif  [18]  and  40.8%  in  Jazan  [16].
he GPADRS  report  [17]  found  that  the  prevalence
f INH  resistance  ranged  from  0%  in  Iceland  to  42.4%
n Uzbekistan,  reaching  4.7%  in  Oman,  9%  in  Jor-
an and  3.9%  in  Yemen.  INH  resistance  is  important
ecause INH  is  a potent  bactericidal  drug  that  is
n important  component  of  the  short  course  anti-
B regimen.  According  to  the  WHO  guidelines  [19],
he suspicion  or  knowledge  of  high  levels  of  iso-
iazid resistance  dictates  that  new  TB  patients
eceive isoniazid,  rifampicin  and  ethambutol  as
n acceptable  alternative  therapy  to  isoniazid  and
ifampicin in  the  continuation  phase.  In  light  of
hese guidelines,  our  ﬁnding  of  high  INH  resistance
s of  considerable  concern  in  deciding  the  treat-
ent regimens  for  new  TB  patients  in  Najran.
Rifampicin  is  the  most  potent  ﬁrst-line  anti-
uberculosis drug  and  an  important  component  of
reatment regimens.  Within  the  last  few  years,  the
HO has  recommended  discontinuing  the  6-month
soniazid  and  ethambutol  regimen  given  during  the
ontinuation  phase  in  favor  of  treatment  with  isoni-
zid and  rifampicin  for  4  months  [20].  This  approach
ill reduce  the  number  of  relapses  and  failures  and
onserve patient  and  national  program  resources.
he RIF  resistance  rate  (2.9%)  was  lower  in  this
tudy  than  other  Saudi  studies,  which  have  found
.7—9.7%  resistance  in  Riyadh  [8,9],  5.1—23.4%
esistance in  Jeddah  [10,11],  2.9—17%  resistance  in
ammam [12,13],  15.3%  resistance  in  Taif  [18]  and
0.4% resistance  in  Jazan  [16].  The  prevalence  of
sis  isolates  to  4  anti-tuberculosis  drugs.
Resistant  isolatesNo.  (%)  TotalNo.  (%)
4  (5.9)
8
(11.8)
2  (2.9)
1  (1.5)
1  (1.5)
10  (14.7) 14
(20.6)4  (5.9)
3  (4.4)  3  (4.4)
1  (1.5)  1  (1.5)
14 (20.6)
butol.
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RIF  resistance  varied  from  0.5%  in  Iceland  to  22.7%
in Azerbaijan  in  the  GPADRS  study  [17],  reaching
1.3%, 2.9%  and  11.7%  in  Oman,  Yemen  and  Jordan,
respectively.
The SPM  and  EMB  resistance  rates  found  in  this
study were  lower  than  the  SPM  and  EMB  resistance
rates reported  in  other  Saudi  studies  [8—13].
In addition  to  the  high  overall  drug  resistance
rate identiﬁed  in  this  study,  another  important
observation was  the  signiﬁcant  number  of  patients
(18, 26.5%)  with  primary  resistance  to  more  than
one drug.  The  data  revealed  that  20.6%  of  patients
in this  study  exhibited  resistance  to  two  drugs,  4.4%
of patients  exhibited  resistance  to  3  drugs,  and  1.5%
of patients  exhibited  resistance  to  4  drugs.  A  pre-
vious report  from  Saudi  Arabia  [21]  showed  that
3.7% of  all  patients  had  resistance  to  at  least  three
drugs,  3.6%  of  patients  had  resistance  to  at  least
two drugs,  and  6.8%  of  patients  had  resistance  to
only one  drug.  TB  that  is  resistant  to  two  or  more
drugs  is  difﬁcult  to  treat  and  often  results  in  treat-
ment failure.  This  resistance  should  be  considered
in prevention  plans  and  when  determining  treat-
ment protocols  in  Najran.
The presence  of  MDR-TB  is  of  considerable  public
health  concern  in  any  community  because  of  both
its mortality  rate  and  low  therapeutic  response  and
the implications  for  speedy  and  energetic  contact
tracing  and  the  management  of  exposed  contacts
[6]. The  MDR-TB  rate  identiﬁed  in  this  study  (20.6%)
is comparable  to  that  (20.9%)  reported  in  a  previ-
ous study  [16]  that  investigated  the  southern  region
of the  country.  Other  Saudi  studies  have  identiﬁed
MDR-TB rates  ranging  from  2.7%  to  19.4%  [8—13].
The median  prevalence  of  MDR-TB  in  new  TB  cases
was 1.6%  in  the  GPADRS  study  [17],  ranging  from  0%
in 8  countries  with  low  TB  prevalence  to  19.4%  in
Moldova and  22.3%  in  Azerbaijan.  This  report  iden-
tiﬁed the  MDR-TB  rates  in  Oman,  Jordan  and  Yemen
as 2%,  13%  and  15%,  respectively.
The prevalence  of  anti-tuberculous  drug  resis-
tance in  previously  untreated  cases  (primary
resistance) is  considered  a  good  epidemiological
indicator  of  the  quality  of  the  TB  treatment  pro-
gram.  Therefore,  a  high  level  of  primary  resistance
indicates the  transmission  of  drug-resistant  TB  in
the community  and  a  poorly  performing  TB  pro-
gram [22].  The  Saudi  Ministry  of  Health  established
the National  Tuberculosis  Control  Committee  to
develop  the  directly  observed  therapy  (DOT)  pro-
gram that  has  been  applied  in  the  Kingdom  since
1999.  However,  Saudi  Arabia’s  success  rate  (65%)
is comparatively  less  than  the  WHO  target  of  85%,
with drug  resistance,  non-compliance  and  over-the-
counter  access  to  anti-TB  treatments  contributing
to the  low  success  rate  [23].A.M.  Asaad,  J.M.  Alqahtani
This  study  had  some  limitations.  First,  the  small
umber  of  cases  and  lack  of  demographic  data
estricted  our  ability  to  describe  the  characteris-
ics of  the  patient  sub-strata.  Second,  the  study  did
ot include  previously  treated  TB  cases  to  deter-
ine secondary  resistance  rates.  Finally,  the  study
ncluded only  pulmonary  M.  tuberculosis  isolates.
onclusion
his  study  showed  that  the  primary  resistance  rate
o four  ﬁrst-line  anti-tuberculous  drugs  and  MDR-TB
ate in  Najran  are  distressingly  high.  Further  studies
re necessary  to  monitor  the  M.  tuberculosis  resis-
ance pattern  continuously,  further  delineate  risk
actors and  formulate  plans  for  preventing  the  dis-
emination of  drug-resistant  isolates,  particularly
DR isolates,  to  the  general  population.
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